TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
TG Therapeutics, Inc. (NASDAQ:TGTX) has received a "Moderate Buy" consensus recommendation from six research firms, with an average 12-month price target of $50.00. The company recently reported a Q3 EPS of $0.14, missing estimates, but revenue of $192.57 million was in line with expectations and up 78% year-over-year. Institutional investors hold approximately 58.58% of the stock.
TGTX PE Ratio & Valuation, Is TGTX Overvalued
TG Therapeutics Inc (TGTX) is currently considered undervalued based on its forward P/S ratio of 4.71 compared to its five-year average of 24.66. Its fair price is estimated to be between $53.47 and $73.90, significantly higher than its current price of $33.53. The company also exhibits robust revenue growth of 78.00%, which supports its P/S ratio relative to competitor averages.
TG Therapeutics Inc. (TGTX) Stock Price | Live Quotes & Charts | NASDAQ
The NASDAQ page for TG Therapeutics Inc. (TGTX) shows its current stock price at $33.00, down $0.58 (-1.73%). The article provides basic stock information, including a chart and a note that there is no available analyst rating or earnings information for the company. It also includes various promotional messages for trading tools and services.
(TGTX) Price Dynamics and Execution-Aware Positioning
This article provides an analysis of Tg Therapeutics Inc. (NASDAQ: TGTX), highlighting strong near- and mid-term sentiment but a weak long-term outlook with elevated downside risk. It details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—alongside multi-timeframe signal analysis for support and resistance levels. The report emphasizes the absence of clear long-term support signals, suggesting caution for long-term investors.
TG Therapeutics stock price forecast: overbought readings persist as TGTX consolidates below SMA-200
TG Therapeutics (TGTX) has obtained an additional $500 million in non-dilutive capital and expanded its share repurchase program to $300 million. While the stock shows a strong short- and medium-term bullish structure, trading above key moving averages, it also exhibits overbought signals. Analysts predict a consolidation between $30.40 and $31.92 in the near term, with a low probability of significant upside due to overbought readings despite momentum indicators confirming a bullish bias.
Nordea Investment Management AB Buys Shares of 79,696 TG Therapeutics, Inc. $TGTX
Nordea Investment Management AB has acquired 79,696 shares of TG Therapeutics (NASDAQ:TGTX) during the fourth quarter, representing a new position valued at approximately $2.36 million. This investment accounts for roughly 0.05% of the company. TG Therapeutics recently reported strong revenue growth of 78% year-over-year to $192.6 million, despite missing EPS estimates, and analysts have a "Moderate Buy" rating with an average target price of $50.
Vanguard disaggregates holdings after realignment — TG Therapeutics (TGTX)
The Vanguard Group filed an amendment to its Schedule 13G/A reporting 0 shares of TG Therapeutics Inc common stock. This change is due to an internal realignment on January 12, 2026, where certain subsidiaries or business divisions will now report beneficial ownership separately. The Vanguard Group therefore no longer beneficially owns the securities reported by these disaggregated entities.
TG Therapeutics announces $100M share buyback program
TG Therapeutics has announced a new share buyback program, authorizing the repurchase of up to $100 million of its common stock. The buyback will be executed through open market purchases or privately negotiated transactions, depending on market conditions, share price, and other factors. The program aims to enhance shareholder value and reflects the company's confidence in its financial position.
TG Therapeutics announces $100M share buyback program
TG Therapeutics has announced a $100 million share repurchase program, demonstrating confidence in the company's financial health and future prospects. Such a program can help increase shareholder value by reducing the number of outstanding shares, thereby boosting earnings per share. This move often signals a belief from management that the company's stock is undervalued.
US$750 Million Credit Facility Could Be A Game Changer For TG Therapeutics (TGTX)
TG Therapeutics has secured a new five-year, US$750 million senior secured credit facility, refinancing a previous US$250 million facility and adding US$500 million in non-dilutive capital. This financing is expected to bolster the company's balance sheet, supporting the commercialization of BRIUMVI, including its subcutaneous launch, and future pipeline development without equity dilution. While boosting financial flexibility, the article notes that the company remains highly dependent on BRIUMVI, facing potential risks from market concentration and payer pressure.
A Look At TG Therapeutics (TGTX) Valuation After New US$750 Million Credit Facility
TG Therapeutics (TGTX) recently secured a new five-year US$750 million credit facility, refinancing existing debt and raising non-dilutive capital. Despite a recent share price decline over the past year, the stock is currently seen as undervalued, with a narrative fair value of $44.43 against a closing price of $30.45. The upcoming launch of subcutaneous BRIUMVI is considered a significant catalyst for future growth, particularly in the multiple sclerosis market.
1,922,410 Shares in TG Therapeutics, Inc. $TGTX Acquired by Congress Asset Management Co.
Congress Asset Management Co. recently acquired 1,922,410 shares of TG Therapeutics (NASDAQ:TGTX), valued at approximately $57.3 million, representing a 1.21% stake in the biopharmaceutical company. Despite missing quarterly EPS estimates, TG Therapeutics reported a significant 78% year-over-year revenue increase to $192.6 million. Wall Street analysts maintain a "Moderate Buy" consensus rating with a $50.00 price target for the stock.
CapEx per share of TG Therapeutics, Inc. – MIL:1TGTX
The article displays the title "CapEx per share of TG Therapeutics, Inc. – MIL:1TGTX" and is a financial page from TradingView for TG Therapeutics, Inc. on Euronext Milan. It indicates that the market is closed and provides navigation for financials, news, community, technicals, forecasts, seasonals, and ETFs related to the company.
TG Therapeutics Credit Deal And Valuation Gap Catch Investor Attention
TG Therapeutics (NasdaqCM:TGTX) has secured a new five-year, $750 million senior secured credit facility with Blue Owl Capital, which is non-dilutive and can expand to $1 billion. This funding is critical for its biopharmaceutical development, R&D, and commercialization plans. The company's stock is currently trading significantly below analyst targets and an estimated fair value, suggesting a large valuation gap and potential upside for investors.
Form 8K TG Therapeutics Inc For: 20 March
This article announces the filing of a Form 8K by TG Therapeutics Inc. for March 20, 2026. The announcement is brief and directly links to the regulatory filing for further details. The company's stock symbol is TGTX.
TG Therapeutics Files Procedural 8-K on Financial Obligation
TG Therapeutics (TGTX) has filed a procedural Form 8-K that cross-references information between items, indicating a technical compliance update rather than new operational or strategic details. This filing does not provide substantive new information regarding the company's business developments. Analysts currently rate TGTX as a Hold with a $29.00 price target, while TipRanks' AI Analyst, Spark, rates it Neutral due to mixed financials but positive valuation and growth guidance.
TG Therapeutics (TGTX) secures $750M 2026 Term Loan maturing 2031
TG Therapeutics has secured a new $750 million 2026 Term Loan, fully drawn on March 18, 2026, to refinance existing debt and restructure its capital. The loan, maturing on March 18, 2031, carries a variable interest rate tied to the company's total net leverage ratio and is secured by substantially all of TG Therapeutics' assets. Principal payments of $37.5 million will commence in 2030, with a potential deferral to maturity based on leverage thresholds.
TG Therapeutics secures $750M credit facility with Blue Owl By Investing.com
TG Therapeutics has secured a new five-year, $750 million senior secured credit facility with Blue Owl Capital, which repays an existing facility and provides a net raise of $500 million. The company plans to use the capital to support share repurchases, business development, and investments in its drug BRIUMVI and pipeline. This financing follows recent financial results showing a miss on EPS but a beat on revenue expectations, and upcoming presentations of BRIUMVI data at a medical meeting.
TG Therapeutics Secures An Additional $500 Million In Non-Dilutive Capital From Blue Owl And Expands Share Repurchase Program To $300 Million
TG Therapeutics has secured an additional $500 million in non-dilutive capital from Blue Owl, significantly boosting its financial resources. Concurrently, the company has expanded its share repurchase program to $300 million. This move aims to enhance shareholder value and provide greater financial flexibility for the company.
TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million
TG Therapeutics announced it has secured a new five-year, $750 million senior secured credit facility with Blue Owl Capital, yielding an additional $500 million in non-dilutive capital after repaying an existing facility. This new funding provides financial flexibility, allowing the company to expand its share repurchase program from $100 million to $300 million and support strategic initiatives. The company highlights the commercial success of its drug BRIUMVI for multiple sclerosis and its commitment to shareholder value.
Fresh $500M gives TG Therapeutics room to triple stock buybacks
TG Therapeutics secured a new five-year $750 million senior secured credit facility with Blue Owl, raising $500 million in net non-dilutive capital after repaying a previous facility. Concurrently, the company expanded its share repurchase program from $100 million to $300 million, signaling confidence in its financial position and commitment to shareholder value. This move aims to provide financial flexibility for strategic initiatives and further investment in their commercial product BRIUMVI and pipeline.
TG Therapeutics Secures an Additional $500 Million in
TG Therapeutics has secured an additional $500 million in non-dilutive capital through an expanded $750 million senior secured credit facility with Blue Owl. This new funding will allow the company to repay its previous $250 million facility, expand its share repurchase program from $100 million to $300 million, and support strategic initiatives and business development for its multiple sclerosis drug, BRIUMVI. The company believes this move enhances its financial flexibility and commitment to shareholder value.
Penn Capital Management Company LLC Grows Stock Position in TG Therapeutics, Inc. $TGTX
Penn Capital Management Company LLC increased its stake in TG Therapeutics (NASDAQ:TGTX) by 17.6%, now holding 521,260 shares valued at $18.88 million. Despite missing Q3 EPS estimates, TG Therapeutics reported a significant 78% year-over-year revenue increase. The company holds a "Moderate Buy" consensus from analysts with an average price target of $50.00.
TG Therapeutics Analysis: Strong Clinical Data Boost Briumvi Prospects
TG Therapeutics (TGTX) stock has risen by 10.77% due to promising FDA designations and strong clinical trial results for its multiple sclerosis drug, Briumvi. The drug showed significant reductions in MS relapse rates and sustained efficacy over five years, positioning it competitively against other treatments. The company projects 2026 revenues of $875M-$900M, primarily from U.S. Briumvi sales, and maintains a solid cash reserve of nearly $200M to support its growth strategy.
How BRIUMVI’s Strong High‑Risk MS Data At TG Therapeutics (TGTX) Has Changed Its Investment Story
TG Therapeutics (TGTX) recently released strong post hoc pooled analysis data for its drug BRIUMVI in highly active relapsing multiple sclerosis, showing significant improvements over teriflunomide. This data reinforces BRIUMVI's potential as an early, high-efficacy treatment and could boost investor confidence, particularly with an upcoming subcutaneous formulation. While the company still relies heavily on BRIUMVI, efforts to expand its autoimmune footprint, like with azercabtagene zapreleucel, aim to diversify its portfolio and reduce concentration risk.
TGTX SEC Filings - Tg Therapeutics Inc 10-K, 10-Q, 8-K Forms
This page provides access to Tg Therapeutics (TGTX) SEC filings, including annual 10-K reports, quarterly 10-Q earnings, 8-K material events, and insider trading forms. Stock Titan offers AI-powered summaries to help investors understand key points from these documents, focusing on the company's B-cell disease pipeline and BRIUMVI commercialization. Recent filings include an insider's proposed sale of common shares, an S-8 registration for an incentive plan, an S-3 shelf registration for various securities, and a Q2 2025 earnings report detailing strong revenue and profitability driven by BRIUMVI sales.
A Look At TG Therapeutics (TGTX) Valuation After New BRIUMVI Efficacy Data In Relapsing Multiple Sclerosis
TG Therapeutics (TGTX) is seen as materially undervalued by Simply Wall St, with a narrative fair value of $44.43 against its current share price of $27.96, primarily driven by the long-term potential of BRIUMVI. The upcoming launch of subcutaneous BRIUMVI is a key catalyst expected to significantly expand its market reach in the anti-CD20 MS segment. Despite positive clinical data and milestones, the stock has underperformed, suggesting a potential discount, though risks from competition remain.
TG Therapeutics, Inc. (NASDAQ:TGTX) Given Average Recommendation of "Moderate Buy" by Brokerages
TG Therapeutics, Inc. (NASDAQ:TGTX) has received a "Moderate Buy" consensus rating from six brokerages, with an average twelve-month target price of $50.00. Several hedge funds have significantly increased their stakes in the company, indicating institutional confidence. Despite missing analyst EPS estimates for the last quarter, the biopharmaceutical company reported strong revenue growth, and analysts expect 0.08 EPS for the current fiscal year.
WINTON GROUP Ltd Buys 113,951 Shares of TG Therapeutics, Inc. $TGTX
WINTON GROUP Ltd significantly increased its stake in TG Therapeutics, Inc. (NASDAQ:TGTX) during the third quarter, acquiring 113,951 shares to now own 125,000 shares valued at approximately $4.52 million. This move is part of broader institutional interest in TG Therapeutics, with 58.58% of the stock held by institutions, including a substantial holding by Goldman Sachs Group Inc. Despite an earnings per share miss in the last quarter, the company reported strong revenue growth and maintains an average analyst rating of "Moderate Buy" with an average target price of $50.00.
BRIUMVI Momentum Leads to Strong Execution for TG Therapeutics (TGTX)
TG Therapeutics (NASDAQ: TGTX) reported its Q4 revenue of $192.6 million, slightly missing consensus estimates, but highlighted strong momentum for its drug BRIUMVI in 2025. The company's CEO, Michael Weiss, noted significant year-over-year growth and ongoing advancements in clinical programs and financial stability. JPMorgan analyst Brian Cheng maintained an "Overweight" rating on TGTX, despite reducing the price target to $46 from $49, indicating a potential upside of over 57%.
The Bull Case For TG Therapeutics (TGTX) Could Change Following New Azer-cel Milestone In Progressive MS
TG Therapeutics (TGTX) reached a clinical milestone with azercabtagene zapreleucel (azer-cel) for progressive multiple sclerosis, triggering a $7.5 million payment from Precision BioSciences. This development adds a differentiated autoimmune program to TG Therapeutics' portfolio, potentially diversifying its treatment options beyond its primary BRIUMVI franchise. While BRIUMVI remains a key revenue driver, this early-stage azer-cel progress introduces a new element to the company's investment narrative and risk profile.
MS patients on BRIUMVI saw far fewer relapses and brain lesions
TG Therapeutics announced the publication of a post hoc pooled analysis from its Phase 3 ULTIMATE I and II studies in Neurology and Therapy, demonstrating that BRIUMVI significantly reduced relapses and MRI activity in patients with highly active relapsing multiple sclerosis (RMS). The analysis showed a 70.8% reduction in annualized relapse rate and markedly higher NEDA-3 rates (77.9% vs 16.4%) with BRIUMVI compared to teriflunomide. These findings reinforce BRIUMVI's efficacy as a high-efficacy treatment option for this patient population.
The Bull Case For TG Therapeutics (TGTX) Could Change Following New Azer-cel Milestone In Progressive MS
TG Therapeutics (TGTX) reached a clinical milestone with Precision BioSciences for azercabtagene zapreleucel (azer-cel) in progressive multiple sclerosis, triggering a US$7.5 million payment. This development diversifies TG Therapeutics' pipeline beyond its primary BRIUMVI franchise, adding an early-stage, higher-risk cell therapy program. While the near-term focus remains on BRIUMVI's performance, the azer-cel progress introduces new potential upside catalysts and reshapes the company's long-term investment narrative.
Bank of America Securities Bearish on TG Therapeutics (TGTX) Post Earnings
Bank of America Securities reaffirmed a Sell rating on TG Therapeutics (TGTX) with a price target of $15, reflecting a 49% downside, following the company's fourth-quarter earnings release. TG Therapeutics reported a net income of $23 million for Q4 and $447.2 million for the full year 2025, with total global revenue of $616 million. The company projects 2026 operating expenses at $350 million plus an additional $100 million for manufacturing, and anticipates sequential revenue growth for Q1 2026 to approximately $185 million to $190 million.
Bank of America Securities Bearish on TG Therapeutics (TGTX) Post Earnings
Bank of America Securities reaffirmed a Sell rating on TG Therapeutics (TGTX) with a $15 price target following the company's fourth-quarter earnings report. Despite reporting a full-year net income of $447.2 million and global revenue of $616 million for 2025, Bank of America's analyst, Alec Stranahan, sees a 49% downside. The company projects Q1 2026 U.S. revenue to grow sequentially to approximately $185 million to $190 million.
TG Therapeutics to present BRIUMVI data at neurology meeting
TG Therapeutics (NASDAQ:TGTX) will present new data on its drug BRIUMVI for relapsing multiple sclerosis at the American Academy of Neurology annual meeting. The presentations will cover real-world clinical experience and updates on a modified dosing regimen's safety and tolerability. Despite a recent stock decline, the company reported strong revenue growth and is considered undervalued by InvestingPro analysis.
TG Therapeutics, Inc. $TGTX Stake Cut by Teachers Retirement System of The State of Kentucky
Teachers Retirement System of The State of Kentucky significantly reduced its stake in TG Therapeutics (NASDAQ:TGTX) by 47.5% in Q3, now holding 38,323 shares valued at approximately $1.38 million. This comes despite TG Therapeutics' revenue rising 78% year-over-year and issuing FY2026 revenue guidance above consensus. While some institutional investors increased their positions, the company missed EPS estimates for the quarter, leaving questions about near-term profitability, though upcoming BRIUMVI data presentations could serve as catalysts.
What researchers will share on BRIUMVI in multiple sclerosis at AAN 2026
TG Therapeutics (NASDAQ: TGTX) announced its schedule for data presentations on BRIUMVI (ublituximab) at the American Academy of Neurology (AAN) 2026 annual meeting, taking place April 18–22 in Chicago. The company will feature two poster presentations on April 21, highlighting real-world data from the ENABLE Phase 4 study and safety/tolerability updates from the ENHANCE study in relapsing multiple sclerosis. These presentations build on recent positive market sentiment for BRIUMVI following strong revenue guidance and long-term efficacy data, indicating continued focus on MS-centric strategies.
TG Therapeutics Announces Schedule of Data Presentations
TG Therapeutics (NASDAQ: TGTX) has announced its schedule of data presentations for BRIUMVI® (ublituximab) in multiple sclerosis at the American Academy of Neurology 2026 annual meeting. The presentations will include real-world clinical experience from the ENABLE study and safety and tolerability updates from the ENHANCE study, both focusing on BRIUMVI's use in relapsing forms of multiple sclerosis. BRIUMVI is an FDA-approved novel monoclonal antibody targeting CD20-expressing B-cells for adults with relapsing forms of multiple sclerosis.
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
TG Therapeutics (NASDAQ: TGTX) announced its schedule of data presentations for BRIUMVI (ublituximab-xiiy) in relapsing forms of multiple sclerosis (RMS) at the American Academy of Neurology (AAN) 2026 annual meeting. The presentations will highlight real-world clinical experience from the ENABLE study and safety/tolerability updates from the ENHANCE study, both focusing on ublituximab. BRIUMVI is a novel glycoengineered monoclonal antibody approved for the treatment of adult patients with RMS.
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
TG Therapeutics (NASDAQ: TGTX) has announced its schedule of data presentations for BRIUMVI (ublituximab-xiiy) in relapsing forms of multiple sclerosis (RMS) at the American Academy of Neurology (AAN) 2026 annual meeting. The presentations will include real-world clinical experience from the ENABLE study and updates on the safety and tolerability of a modified ublituximab dosing regimen from the ENHANCE study. BRIUMVI is a novel glycoengineered monoclonal antibody designed to efficiently deplete B-cells and is approved for treating adults with RMS.
Assessing TG Therapeutics (TGTX) Valuation After BRIUMVI Growth Guidance And Pipeline Updates
TG Therapeutics (TGTX) is currently undervalued, with a fair value of $44.43 against a market price of $29.03, despite recent share price weakness. The company's BRIUMVI drug, especially with the upcoming subcutaneous launch targeting 35-40% of the anti-CD20 MS market, is a key growth driver. Investors should consider the potential for rapid revenue growth and rising profitability that supports this higher valuation.
TG Therapeutics Azer Cel Milestone Adds Depth To Autoimmune Valuation Story
TG Therapeutics (NasdaqCM:TGTX) has announced a new clinical milestone for azercabtagene zapreleucel (azer cel) in progressive multiple sclerosis, stemming from a licensing agreement with Precision BioSciences. This development diversifies TG Therapeutics' autoimmune pipeline beyond its existing BRIUMVI franchise. Despite recent stock volatility, the azer cel progress provides a new valuation context and potential long-term revenue streams for investors, though a major risk regarding non-cash earnings quality is noted.
TG Therapeutics Announces Schedule of Data Presentations
TG Therapeutics has announced its schedule of data presentations for BRIUMVI (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS) at the American Academy of Neurology 2026 annual meeting. The presentations will include real-world clinical experience from the ENABLE study and updates on the safety and tolerability of a modified ublituximab dosing regimen from the ENHANCE study. BRIUMVI is a novel monoclonal antibody indicated for the treatment of adults with RMS.
TG Therapeutics Announces Schedule of Data Presentations
TG Therapeutics announced its schedule of data presentations for BRIUMVI (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting. The presentations will highlight real-world clinical experience and safety data from the ENABLE and ENHANCE studies. BRIUMVI is a novel monoclonal antibody indicated for the treatment of adults with relapsing forms of multiple sclerosis.
Reports Suggest TG Therapeutics May Be Scaling Back Operations Amid Speculation on CafePharma Forum
Reports are circulating that TG Therapeutics may be scaling back its operations, sparked by a discussion on the CafePharma forum titled "TG Packing Up?". The post, from March 5, 2026, has led to speculation about potential restructuring or reduction in the pharmaceutical firm's activities. No official statement has been issued by TG Therapeutics to confirm or deny these rumors, leaving the situation unclear for industry observers.
TG Therapeutics Q2 EPS Estimate Lowered by HC Wainwright
HC Wainwright has lowered its Q2 2026 EPS estimate for TG Therapeutics to $0.27, and modestly reduced earnings forecasts through 2030, citing potential reduced margin or growth assumptions. This revision comes despite TG Therapeutics raising its FY 2026 revenue guidance significantly to $875-$900 million, which is above Street expectations. The lack of EPS guidance from TG Therapeutics for FY 2026, coupled with the lowered estimates from analysts, creates near-term uncertainty for the biopharmaceutical company despite strong top-line projections.
TG Therapeutics Milestone With Azer Cel Adds New Dimension To Growth Story
TG Therapeutics (NasdaqCM:TGTX) has reached a clinical milestone with Precision BioSciences for azercabtagene zapreleucel (azer-cel) in a Phase 1 trial for progressive multiple sclerosis, marking an expansion of its pipeline into autoimmune diseases. This development allows TG Therapeutics to leverage allogeneic CAR T cell therapy beyond its core product, BRIUMVI, and is part of a strategy to diversify its growth drivers through partnerships. Investors should monitor future clinical readouts for azer-cel and how TG Therapeutics balances this new investment with the continued commercialization of BRIUMVI.
TG Therapeutics Q4 EPS Forecast Lowered by HC Wainwright
HC Wainwright has lowered its Q4 2026 EPS forecast for TG Therapeutics (NASDAQ:TGTX) to $0.41 from $0.47, with the consensus full-year EPS standing at $0.08. This revision follows TG Therapeutics reporting Q4 EPS of $0.14, missing the consensus estimate of $0.35, despite revenue increasing by approximately 78% year-over-year. Analysts remain mixed on the stock, which traded down about 1.8%, with a consensus rating of "Moderate Buy" and an average price target of $50.00.
Is TG Therapeutics’ 2025 Earnings Miss and BRIUMVI Guidance Shift Altering The Investment Case For TGTX?
TG Therapeutics reported mixed Q4 2025 results, with revenue up but earnings per share below analyst expectations. Despite this, the company raised its 2026 BRIUMVI revenue guidance, which is central to its investment narrative focusing on the drug's continued success and expansion. Investors are cautioned about the single product dependency and potential rising payer pressure on drug pricing.
